|SIGA Technologies, Inc.|
660 Madison Avenue
United States - Map
SIGA Technologies, Inc. is engaged in the development and commercialization of pharmaceutical solutions for serious unmet medical needs and biothreats. The companys lead product is Arestvyr, an orally administered antiviral drug that targets orthopoxviruses. It is also developing dengue antiviral and anti-arenavirus drug candidates, which are in pre-clinical stage. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York. On September 16, 2014, SIGA Technologies, Inc. filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of New York.
|SIGA Technologies, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 1; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Eric A. Rose M.D.,
Exec. Chairman, Chief Exec. Officer and Member of National Biodefense Science Board
|Mr. Daniel J. Luckshire ,
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Sec.
|Dr. Dennis E. Hruby Ph.D.,
Chief Scientific Officer and VP
|Mr. William J. Haynes II,
Exec. VP and Gen. Counsel
| Doris McCarthy ,
Director of Admin.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|